Dr. Deepti Arun Chopra, MD

Dr. Chopra practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Chopra's NPI, 1801021019, was assigned on May 18, 2009. Dr. Chopra graduated from Grant Medical College in 2005. Dr. Chopra holds Texas license Q9592.

Dr. Chopra's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Chopra's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chopra practices. Vendor and product names are available with a free account.

Psychiatry is Dr. Chopra's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Chopra is board certified in psychiatry by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Chopra's licenses on file in 3 states: Texas, Oklahoma and Connecticut.

Dmand AI lists adjustment disease, anxiety, bipolar disorder, depression, non-alzheimer's dementia (chronic), schizophrenia and tobacco use among the conditions Dr. Chopra treats.

CMS data shows 291 Medicare services from Dr. Chopra across 7 procedure codes in 2024, for 121 Medicare patients. Medicare paid $21,357 for them.

CMS counts 121 Medicare patients who saw Dr. Chopra in 2024. The largest group is 65 to 74, with 67 patients. 75% of them have mood disorders, and 74% have high blood pressure. 12% are also on Medicaid. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chopra's median patient age at 58, with 79% women.

In 2024, Dr. Chopra wrote 405 Medicare Part D claims for 90 patients. 100% of them were for generic drugs. CMS names the drug for 344 of them, across 9 drugs with 11 or more claims each, at $3,785 in total drug cost. In 2023, CMS named 270 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Chopra for performance year 2024, reported as part of a group. Dr. Chopra accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chopra as offering telehealth.

Dmand AI links 75 papers to Dr. Chopra, published from 2009 to 2024. 2018 was the busiest year, with 9. The most frequent topics are Ultraviolet Rays, Keratinocytes and Reactive Oxygen Species. Dr. Chopra has published most often in Curr Drug Saf. Dr. Chopra's most frequent co-authors are Gregory P. Reece, MD, Summer E. Hanson and Thao P. Bui, MD.

CMS Open Payments shows 1 general payment to Dr. Chopra from 1 drug or device company in 2025. Food and beverage make up the largest share, 100% of the total. ACADIA Pharmaceuticals Inc paid the most, $20.

Dr. Chopra graduated from Grant Medical College in 2005.

Dr. Chopra is in network with 16 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.